Characteristics and Outcome of Streptococcus pneumoniae Endocarditis in the XXI Century. A Systematic Review of 111 Cases (2000–2013)

Characteristics and Outcome of Streptococcus pneumoniae Endocarditis in the XXI Century A Systematic Review of 111 Cases (2000–2013) Viviana de Egea, MD, Patricia Mun˜oz, MD, PhD, Maricela Valerio, MD, Arı ´stides de Alarco ´n, MD, PhD, Jose ´Antonio Lepe, MD, PhD, Jose ´M. Miro ´, MD, PhD, Juan Ga ´lvez-Acebal, MD, PhD, Pablo Garcı ´a-Pavı ´a, MD, PhD, Enrique Navas, MD, PhD, Miguel Angel Goenaga, MD, Marı ´a Carmen Farin˜as, MD, PhD, Elisa Garcı ´aVa ´zquez, MD, PhD, Mercedes Marı ´n, PharmD, PhD, and Emilio Bouza, MD, PhD, and the GAMES Study Group Abstract: Streptococcus pneumoniae is an infrequent cause of severe infectious endocarditis (IE). The aim of our study was to describe the epidemiology, clinical and microbiological characteristics, and outcome of a series of cases of S. pneumoniae IE diagnosed in Spain and in a series of cases published since 2000 in the medical literature. We prospectively collected all cases of IE diagnosed in a multicenter cohort of patients from 27 Spanish hospitals (n ¼2539). We also performed a systematic review of the literature since 2000 and retrieved all cases with complete clinical data using a pre-established protocol. Predictors of mortality were identified using a logistic regression model. We collected 111 cases of pneumococcal IE: 24 patients from the Spanish cohort and 87 cases from the literature review. Median age was 51 years, and 23 patients (20.7%) were under 15 years. Men accounted for 64% of patients, and infection was community-acquired in 96.4% of cases. The most important underlying conditions were liver disease (27.9%) and immunosuppression (10.8%). A predisposing heart condition was present in only 18 patients (16.2%). Pneumococcal IE affected a native valve in 93.7% of patients. Left-sided endocarditis predominated (aortic valve 53.2% and mitral valve 40.5%). The microbiological diagnosis was obtained from blood cultures in 84.7% of cases. In the Spanish cohort, nonsusceptibility to penicillin was detected in 4.2%. The most common clinical manifestations included fever (71.2%), a new heart murmur (55%), pneumonia (45.9%), meningitis (40.5%), and Austrian syndrome (26.1%). Cardiac surgery was performed in 47.7% of patients. The in-hospital mortality rate was 20.7%. The multivariate analysis revealed the independent risk factors for mortality to be meningitis (OR, 4.3; 95% CI, 1.4–12.9; P<0.01). Valve surgery was protective (OR, 0.1; 95% CI, 0.04–0.4; P<0.01). Streptococcus pneumoniae IE is a community-acquired disease that mainly affects native aortic valves. Half of the cases in the present study had concomitant pneumonia, and a considerable number developed meningitis. Mortality was high, mainly in patients with central nervous system (CNS) involvement. Surgery was protective. (Medicine 94(39):e1562) Abbreviations: CLSI = Clinical & Laboratory Standards Institute, CNS = central nervous system, COPD = chronic obstructive pulmonary disease, GAMES = Grupo de apoyo al manejo de la endocarditis, HIV = human immunodeficiency virus, ICE = International Collaboration on Endocarditis study group, IE = infectious endocarditis, IPD = invasive pneumococcal disease, MIC = minimum inhibitory concentration, PIE = pneumococcal infectious endocarditis. INTRODUCTION Invasive pneumococcal disease (IPD) remains a major health problem that affects 20 to 35,000 patients per year in the USA and Europe and causes 3500 to 5800 related deaths. 1,2 Streptococcus pneumoniae was responsible for 15% of all cases of IE in the preantibiotic era, 3,4 whereas in the 1980 to 1990s prevalence was <3%. 3,5 However, recent data on the incidence of pneumococcal IE (PIE) are lacking. Diagnosis, treatment, and outcome have improved during the last 15 years, thanks to routine immunization, new rapid molecular and imaging techniques, new cutoff minimum inhibitory concentration (MIC) criteria for penicillin sensitivity, and multidisciplinary management 6 . Most major studies on PIE were published before the year 2000.The objectives of this study were to analyze the epidemiology and characteristics of PIE in a large prospective multicenter series and to review cases of PIE reported during the last 14 years. Editor: Mistiaen Wilhelm. Received: March 27, 2015; revised and accepted: August 18, 2015. From the Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Maran ˜o´n (VDE, PM, MV, MM, EB); Department of Medicine, Universidad Complutense, Madrid (UCM), Spain (PM, MM, EB); CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III (CIBERES), Madrid, Spain (PM, MM, EB); Instituto de Investigacio´n Sanitaria Gregorio Maran ˜o´n (IiSGM) Madrid, Spain (PM, MV, MM, EB); Microbiology and Infectious disease department, Hospital Universitario Virgen del Rocio, Sevilla (ADA, JAL); Infectious Diseases Department. Hospital Clinic-IDIBAPS, University of Barcelona (Barcelona) (JMM); Department of Medicine, Unidad Clı´nica Intercentros de Enfermedades Infecciosas, Microbiolo gı´a y Medicina Preventiva Hospital Universitario Virgen Macarena. Departamento de Medicina. Universidad de Sevilla (JG-A); Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid (PG-P); Hospital Ramo´n y Cajal, Madrid (EN); UEI HU Donostia, San Sebastia´n (MAG); Hospital Marque´s de Valdecilla, University of Catabria, Santander (MCF); and Hospital Clı´nico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigacio´n Biosanitaria (IMIB), Facultad de Medicina-Universidad de Murcia, Spain (EGV). Correspondence: Patricia Mun ˜oz, Servicio de Microbiologı´a Clı´nica y Enfermedades Infecciosas, Hospital General Universitario ‘‘Gregorio Maran ˜o´n’’, Doctor Esquerdo 46, Madrid, Spain (e-mail: [email protected]). Maricela Valerio, Servicio de Microbiologı´a Clı´nica y Enfermedades Infecciosas, Hospital General Universitario ‘‘Gregorio Maran ˜o´n’’, Doctor Esquerdo 46, Madrid, Spain (e-mail: [email protected] com.mx). Funding sources: none. The authors have no conflicts of interest to disclose. Copyright #2015 Wolters Kluwer Health, Inc. All rights reserved. This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ISSN: 0025-7974 DOI: 10.1097/MD.0000000000001562 Medicine® SYSTEMATIC REVIEW AND META-ANALYSIS Medicine Volume 94, Number 39, October 2015 www.md-journal.com |1 MATERIAL AND METHODS Setting and Study Design We used the database of GAMES (Grupo de Apoyo al Manejo de la EndocarditiS), which is a prospective Spanish registry of consecutive patients with IE defined according to the modified Duke criteria 7 diagnosed between January 1, 2008 and December 31, 2013 in 27 Spanish hospitals (n ¼2539). Multidisciplinary teams completed a standardized case report form. Regional and local (Comite´E ´tico de Investigacio´n Clı´nica Hospital General Universitario Gregorio Maran ˜o´n - A ´rea 1) ethics committees approved the study, and patients gave their informed consent. The follow-up period lasted 1 year. In order to increase the number of cases, we also included 4 patients prospectively recruited in the coordinating center from 2004 to 2008 (n ¼228). Additionally, the literature was reviewed for articles in English, French, and Spanish published from 2000 to 2013 using the medical subject headings ‘‘Streptococcus pneumoniae endocarditis’’, ‘‘pneumococcal endocarditis’’, and ‘‘pneumococcus endocarditis’’. We also searched reference lists to identify additional reports of S. pneumoniae endocarditis. If necessary, the authors were contacted in order to obtain additional information. Cases with insufficient clinical information were excluded from this analysis. All cases recorded during the study period (2000–2013) were included in a database for statistical analysis. Diagnosis of IE was based on the Duke criteria combined with identification of S. pneumoniae in blood and/or in valve tissue. Identification was based on traditional microbiologic cultures or molecular techniques. The IE episode was considered community-acquired or health care associated based on the classification of the International Collaboration on Endocarditis study group (ICE). 8 Predisposing conditions for IE were registered, including previous valve disease, previous valve replacement, and presence of intracavitary devices, including pacemakers and implantable cardioverter defibrillators. Mortality during hospitalization and mortality after follow-up was recorded. The new values introduced in 2008 by the Clinical & Laboratory Standards Institute (CLSI) were used to determine susceptibility to penicillin and cefotaxime in the Spanish cohort. 9 In the cases from the literature, when MIC values were not provided, the published susceptibility (resistant or susceptible) was accepted. Statistical Analysis We calculated the incidence of S. pneumoniae endocarditis as the number of episodes detected each year divided by the number of inhabitants in the hospital catchment area (in hundreds of thousands) and by the number of hospital admissions (in thousands). The statistical analysis was carried out using SPSS 15.0 (SPSS, Chicago, IL). In the univariate analysis, categorical variables were compared using the chi-square test or the Fisher’s exact test. Non-normally distributed continuous variables were compared using the ttest, and normally distributed variables were compared using the ttest or analysis of variance. In order to assess potential changes in the characteristics of pneumococcal endocarditis, we compared cases from the Spanish cohort with cases collected from the literature review. Independent factors related to in-hospital mortality were also assessed using a backwards logistic regression model adjusted for sex, meningitis (yes vs no), and surgical treatment for the endocarditis episode (yes vs no). RESULTS Epidemiology We analyzed 111 patients with PIE: 24 cases from the Spanish GAMES cohort (Table 1) and 87 from the literature published between 2000 and 2013. 4,10–70 We excluded cases diagnosed before 2000 6,22,26,62,71,72 and cases for which clinical information was insufficient. 73–79 Streptococcus pneumoniae was identified in 24 cases, namely, 0.86% of the 2539 IE episodes registered in the GAMES cohort. Epidemiological Characteristics The epidemiological characteristics of the 111 patients and the comparison between the Spanish series and the cases from the literature are shown in Table 2. Median age was 51 years (IQR, 26–63) and 71 patients were men (64%). All but 4 episodes (3.6%) were community acquired. The most common underlying condition was liver disease (27.9%), followed by immunosuppression (10.8%) and splenectomy or asplenia (8.1%). A predisposing heart condition was present in 20 patients (18%): 11 with congenital heart disease, 8 with previous valve disease (2 prosthetic valves), and 1 patient with a previous history of IE and valve replacement. Patients from the Spanish cohort were significantly older than those from the literature, with a median age of 57 (50–69) versus 47 (15–61) years (P0.001), and more frequently had previous liver disease (45.8% vs 23% P0.03) and predisposing heart valve conditions (27.3% vs 2.4% P0.001). Clinical Presentation Considering all cases, the most prevalent clinical manifestations were fever (71.2%), new heart murmurs (55%), and vascular phenomena that were only present in 5 patients (4.5%): 2 with disseminated petechiae, 1 with Osler nodes and Janeway lesions, 1 with subconjunctival hemorrhage and Roth spots, and 1 case with splinter hemorrhages. At diagnosis of endocarditis, 42% of patients presented concomitant pneumonia and 40.5% presented meningitis. Complete Austrian syndrome (endocarditis, meningitis, and pneumonia) was present in 29 patients (26.1%) (Table 2). PIE was predominantly left-sided (aortic valve in 53.2% and mitral valve in 40.5%) and involved a native valve in 93.7% of cases. The Spanish cohort more commonly presented prosthetic valve endocarditis than the cases collected from the literature (16.7% vs 3.4%, P0.03). Diagnostic Methods Considering the whole series, S. pneumoniae was recovered from blood cultures in 84.7% of the patients and from other cultures in 73.3% of the cases where data were available. Cerebrospinal fluid was positive in 33.3% and valve cultures in 21.2% (Table 3). Data regarding molecular techniques performed on valve tissue were available for 9 patients of the 24 cases from the Spanish cohort; the results were positive for S. pneumoniae for all of them. Furthermore, in the Spanish cases, antimicrobial susceptibility was analyzed using the new cutoffs introduced in 2008, whereas in most reports from the literature, MIC values were not included. Taking this characteristic limitation of retrospective data into account, penicillin nonsusceptibility rates were 4.2% in the Spanish cohort and 25.9% in the literature (P¼0.05). de Egea et al Medicine Volume 94, Number 39, October 2015 2|www.md-journal.com Copyright #2015 Wolters Kluwer Health, Inc. All rights reserved. TABLE 1. Characteristics of 24 Patients With Streptococcus pneumoniae Infective Endocarditis From the GAMES Cohort (2004–2013) No/ Year Age/Sex Place of Acquisition S. pneumoniae Serotype Underlying Disease Affected Valve Major Echocardiography Findings Other Clinical Manifestations Complications Treatment Cardiac Surgery Outcome 2004 1,  77/F Community 18C COPD, asthma, heart failure, prosthetic aortic and mitral valve, immunosuppressors, peripheral vascular disease Prosthetic aortic and mitral Vegetation None None 1) Ceftriaxone 40d No Cure 2005 2,  56/M Community 8 Chronic hepatitis due to hepatitis C, previous history of IVDU Aortic native valve Vegetation Austrian syndrome, meningitis, pneumonia, splenomegaly Heart failure, CNS embolism and hemorrhage, renal failure renal replacement therapy, VAP due to P. aeruginosa, septic shock 1) Cefotaxime 24dþ vancomycin 4dþ gentamicin 22d 2) Meropenem 12d 3) Piperacillin/ tazobactam 20 d Yes Death 2006 3,  55/M Community 8 Alcoholic liver disease, alcoholism, smoker Tricuspid native valve Vegetation Austrian syndrome, meningitis, pneumonia CNS embolism and hemorrhage, subacute hydrocephalus, pleural effusion, joint infection, multiorgan failure due to septic shock 1) Cefotaxime 25d þ vancomycin 3d þ gentamicin 30d þclindamycin 10 d No Death 2) Meropenem 25d 2006 4,  41/M Community 5 Chronic hepatitis C, active IVDU Native tricuspid valve Vegetation Pneumonia Mild tricuspid insufficiency 1) Ceftriaxone 16 d No Cure 2) Levofloxacin 14 d 2008 5 54/M Community Unknown Chronic liver disease, diabetes, chronic alcoholism Native aortic valve Aortic vegetation and abscess Pneumonia Heart failure due to severe valve regurgitation, death before surgery 1) Ceftriaxone 20 d No Death 2008 6,  51/M Community 9V B-cell lymphoma, previous IE, previous cardiac surgery, cocaine use, pulmonary TB, asplenia, no vaccination Prosthetic aortic valve Perivalvular abscess Austrian syndrome, meningitis, pneumonia, splenomegaly Aortic root abscess, heart failure due to periprosthetic leak 1) Vancomycin 17d þcefotaxime 8d 2) Ceftriaxone 30d No Cure 2008 7 82/M Community Unknown COPD Native mitral valve Mitral vegetation Meningitis Death before surgery 1) Ceftriaxone 3d No Death 2008 8 79/F Community Unknown Chronic renal failure, previous calcified valve disease Native mitral valve Mitral vegetation Previous ORL disease, meningitis None 1) Ceftriaxone 42d No Cure 2009 9,  55/M Health care–related 8 Klinefelter syndrome, chronic cardiac failure, severe renal failure, hemodialysis, mild alcoholic liver disease, rheumatic disease (aortic stenosis), allergy to betalactams Native aortic and mitral valve Vegetation, aortic perforation Pneumonia Aortic root perforation 1) Linezolid 5d 2) Ceftriaxone 42d Yes Cure but 3 mo later had IE due to E.faecalis 2009 10 48/M Community Unknown COPD, HIV Native aortic valve Aortic valve vegetation and perforation Pneumonia Heart failure due to severe aortic insufficiency 1) Ceftriaxone 10d Yes Cure 2) Teicoplanin 14d 2009 11 55/M Community Unknown Chronic alcoholism Native aortic valve No findings (autopsy diagnosis) Meningitis, altered mental status Encephalopathy 1) Ceftriaxone þ vancomycin 8d No Death 2009 12 51/M Community Unknown None Native aortic valve Aortic vegetation None Heart failure due to severe valve regurgitation 1) Cefotaxime þ gentamicin 6d Yes Cure 2) Ceftriaxone 20d 2010 13 67/M Community Unknown None Native aortic valve Aortic valve perforation Aortic valve regurgitation None 1) Ceftriaxone 5d þ gentamicin 5d Yes Cure 2) Vancomycin 38d 2010 14 84/M Community Unknown None Native aortic valve Aortic vegetation Pneumonia CNS embolism, multiorgan failure 1) Ceftriaxone 12d No Death 2011 15,  44/M Community 20 Diabetes, mild alcoholic liver disease, chronic alcoholic, pancreatitis, tobacco and cannabis smoking Native aortic valve Vegetation Splenomegaly, avascular necrosis of right hip Heart failure due to mitral and tricuspid insufficiency 1) Vancomycin 3d þ levofloxacin 4d 2) Ceftriaxone 38d Yes Cure 2011 16,  63/M Community Unknown Colonic adenocarcinoma, chronic hepatitis C, esophageal varices, umbilical hernia Native aortic valve Vegetation Pneumonia and empyema Heart failure due to mitral and tricuspid insufficiency, pulmonary embolism, septic thrombophlebitis 1) Ceftriaxone 15d þ levofloxacin 15d No Death Medicine Volume 94, Number 39, October 2015 Streptococcus Pneumoniae Endocarditis Copyright #2015 Wolters Kluwer Health, Inc. All rights reserved. www.md-journal.com |3 No/ Year Age/Sex Place of Acquisition S. pneumoniae Serotype Underlying Disease Affected Valve Major Echocardiography Findings Other Clinical Manifestations Complications Treatment Cardiac Surgery Outcome 2011 17,  1 mo/M Community 11A None Native mitral valve Vegetation Non resolving otitis media Heart failure due to mitral stenosis 1) Amoxicillinclavulanate 7 d Yes Cure but non-related- death one year later Vaccinated 2) Cefotaxime 26 dþ vancomycin 21 d 3) Ceftriaxone 11 d 4) Cefixime 11 d 2011 18 48/M Community Unknown Previous rheumatic valve disease Native aortic and mitral valves Aortic and mitral vegetation Endophthalmitis Liver and spleen abscess 1) Vancomycin þ ceftriaxone 4 d No Cure 2) Penicillin 29 d 2011 19 65/F Community Unknown Asthma, chronic renal failure, previous valve disease (rheumatic) Prosthetic mitral valve Prosthetic mitral vegetation None VAP 1) Ceftriaxone 34 d Yes Cure 2011 20 63/M Community Unknown Heart failure, chronic liver disease, previous valve disease (rheumatic), prosthetic mitral and aortic valve, pacemaker Prosthetic mitral valve Prosthetic mitral vegetation None None 1) Penicillin þ gentamicin 12 d 2) Ceftriaxone 30 d No Cure 2012 21,  58/F Community Unknown Ischemic cardiomyopathy, myocardial infarction, diabetes, hypertension, osteoarthritis, obesity Native aortic valve Vegetation Soft tissue abscess, ankle osteomyelitis, liver abscess, chorioretinitis Heart failure due to severe aortic insufficiency, surgical wound infection due to A. baumannii 1) Ceftriaxone 20 d Yes Cure 2012 22  84/F Community 23A Hypothyroidism, cholecystectomy Native mitral valve Vegetation, perivalvular abscess Pharyngitis, multiple cerebral ischemic areas due to embolisms Perivalvular abscess, severe mitral insufficiency, surgical complications requiring pericardium patch for left atrium, nosocomial K.pneumoniae UTI 1) Ceftriaxone 57 d Yes Death 2012 23,  70/F Community 12F Peripheral vascular disease, stroke, mild renal failure, chronic hepatitis C, cryoglobulinemia Native aortic valve Vegetation Mental status alteration without meningitis Nosocomial E. coli UTI 1) Ampicillin þ levofloxacin 1 d 2) Ceftriaxone 26 d No Cure 2013 24 50/F Community Unknown Diabetes Native aortic valve Aortic vegetation and perforation Meningitis Heart failure due to severe aortic regurgitation 1) Ceftriaxone 30 d Yes Cure 2) Ampicillin 7 d 3) Vancomycin 11 d CNS ¼central nervous system, COPD ¼chronic obstructive pulmonary disease, F ¼female, HIV ¼human immunodeficiency virus, IE ¼infective endocarditis, IVDU ¼intravenous drug user, M¼male, ORL ¼otorhinolaryngologic, TB ¼tuberculosis, UTI ¼urinary tract infection, VAP ¼ventilator-associated pneumonia.  Cases from reference center. de Egea et al Medicine Volume 94, Number 39, October 2015 4|www.md-journal.com Copyright #2015 Wolters Kluwer Health, Inc. All rights reserved. Data on capsular serotypes were available for 27 cases from the whole series and revealed marked diversity. The most common serotypes were 18C, 23F, and 8 (3 each). Vaccination data were available for only 13 patients, of whom 4 had been vaccinated. We could not demonstrate any association between the serotype and clinical manifestations, complications, or patient outcome. For the entire cohort, echocardiography was performed in 98.2% of patients (Table 3). Both of the 2 patients without echocardiographic data died before diagnosis, which was confirmed by autopsy. Major findings included vegetations (80.2%), valve rupture (18%), and abscesses (8.1%). Treatment and Outcome Analyses of the whole series revealed that third-generation cephalosporins were used in 90.1% of the patients, vancomycin in 44.1%, and penicillin in 16.2%. Combined therapy was administered in 62.5% of cases and the most common combination was third-generation cephalosporins with vancomycin (15%). Almost half of the patients underwent cardiac surgery for the IE episode (47.7%) (Table 3). There was an indication for surgery in 67.4% of the patients, and the indications were: inadequate source of infection control or severe sepsis (17.7%), heart failure (12.5%), myocardial extension of the infection (ring abscess, perivalvular tissue involvement, or aortic fistula) (8.3%), valve rupture or severe valve malfunction (6.3%), systemic and CNS embolism (3.1%), IE after prosthetic valve replacement (2%). More than 1 indication was present in 11.5% of the cases. All of these events represent complications of the IE episode. Regarding the time of the surgery, 50% of patients underwent surgery <1 week after the IE diagnostic. We could not found any differences in the outcome of the patients regarding time of surgery. The most common complications were heart failure (33.3%) and central nervous system embolisms (13.5%). Non-CNS embolism was reported in 31 patients (27.9%), including septic arthritis (7.2%) and endophthalmitis (6.3%). Related mortality was 20.7%. As expected, mortality was higher in the Spanish cohort (33% vs 17%, P¼0.09), which included patients with more severe conditions (older age, more TABLE 2. Demographic and Clinical Characteristics of 111 Patients With Streptococcus pneumoniae Endocarditis Characteristics Total Cohort N ¼111 (%) Spanish Cohort n ¼24 Literature Review n ¼87 P Age (median, IQR) 51 (26–63) 57 (50–69) 47 (15–61) 0.001 Sex Male 71 (64) 18 (75) 53 (60.9) 0.2 Underlying medical condition Liver disease 31 (27.9) 11 (45.8) 20 (23) 0.03 Alcoholism 22 (19.8) 6 (25) 16 (20.5) Chronic hepatitis C 5 (4.5) 3 (12.5) 2 (2.3) Others 3 (2.7) 2 (8.3) 1 (1.1) Immunosuppression 12 (10.8) 3 (12.5) 9 (11.5) 1 HIV/AIDS 6 (5.4) 1 (4.3) 5 (6) Malignancy 4 (3.6) 1 (4.3) 3 (3.6) Solid organ transplantation 1 (0.9) 0 (0) 1 (1.1) Splenectomy or asplenia 9 (8.1) 0 (0) 9 (11.7) 0.1 COPD 8 (7.2) 4 (16.7) 4 (5.1) 0.08 Intravenous drug use 4 (3.6) 2 (8.3) 2 (2.6) 0.2 Previous heart disease 20 (18) 6 (25.0) 14 (16) 0.2 Congenital heart disease 11 (9.9) 0 (0) 11 (12.9) 0.1 Valve disease 8 (7.2) 6 (27.3) 2 (2.4) 0.001 Previous endocarditis 6 (5.4) 1 (4.2) 5 (6.4) 1 Clinical manifestations Fever 79 (71.2) 21 (87.5) 58/61 (95,1) 0.6 Heart murmur 61 (55) 17 (77.3) 44/55 (80.0) 0.7 Pneumonia 51 (45.9) 9 (37.5) 42/84 (50.0) 0.3 Meningitis 45 (40.5) 7 (29.2) 38/84 (45.2) 0.2 Austrian syndrome 29 (26.1) 3 (12.5) 26/84 (31.0) 0.1 Vascular phenomena 5 (4.5) 0 (0) 5/62 (8.1) 0.3 Splenomegaly 3 (2.7) 3 (13) 0 (0) 0.02 Type of valve Native 104 (93.7) 20 (83.3) 84 (96.6) 0.03 Prosthetic 7 (6.3) 4 (16.7) 3 (3.4) 0.03 Affected valve Aortic 59 (53.2) 14 (58.3) 45 (51.7) 0.6 Mitral 45 (40.5) 10 (41.7) 35 (40.2) 1 Tricuspid 14 (12.6) 3 (12.5) 11 (12.6) 1 More than 1 valve affected 15 (13.5) 3 (12.5) 12 (13.8) 1 COPD ¼chronic obstructive pulmonary disease. Medicine Volume 94, Number 39, October 2015 Streptococcus Pneumoniae Endocarditis Copyright #2015 Wolters Kluwer Health, Inc. All rights reserved. www.md-journal.com |5 underlying diseases, and more frequent prosthetic valve involvement). The risk factors for mortality identified in the univariate analysis were peripheral embolism (47.8% vs 22.7%, P¼0.03), CNS embolism (34.8% vs 8%, P¼0.003), meningitis (65.2% vs 34.1%, P¼0.009), and Austrian syndrome (43.5% vs 21.6%, P¼0.059), and are summarized in Table 4. Cardiac surgery was a protective factor against mortality (17.4% vs 55.7%, P<0.01). The multivariate analysis demonstrated that the independent risk factors for mortality were meningitis (OR, 4.3; 95% CI, 1.4–12.9 P<0.01), whereas valve surgery was protective (OR, 0.1; 95% CI, 0.04–0.4; P<0.01). DISCUSSION We performed a 14-year retrospective study of the epidemiology, clinical manifestations, complications, and outcome of PIE. PIE affected young adult patients with previous liver disease and alcoholism, even those with no history of valve disease. It is more frequent in left-sided valves. Interestingly, pneumonia was present in half of all cases and Austrian syndrome in a quarter. Despite advances in modern medicine, mortality remains high (20.7%), and complications due to valve dysfunction are common. Almost half of the patients in our study required valve surgery, and the only risk factor associated with better survival was early heart surgery. In a publication of the International Collaboration on Endocarditis-Prospective Cohort, the prevalence of all types of streptococcal IE was 6% (excluding viridans group streptococci and Streptococcus bovis). 80 No recent prospective data are available for PIE. The US Invasive Pneumococcal Disease (IPD) surveillance report showed 33,500 cases of IPD (10.6/ 100,000) and 3500 deaths (1.1/100,000). 1 In Europe, according to the European Centre for Disease Prevention and Control, 26 EU/EEA countries reported 20,843 confirmed cases of IPD in 2011 (5.59/100,000), with 5771 related deaths (10.3%). 2 Immunosuppressed patients (solid organ transplant, malignancy, and HIV infection) and patients with specific chronic disorders (cirrhosis, alcoholism, COPD, and diabetes mellitus) have a higher risk of developing IPD. Moreover, several studies proposed that these factors are even more important than the specific pneumococcal serotype as determinants of TABLE 3. Diagnostic Characteristics and Complications of 111 Patients With Pneumococal Endocarditis Variable Total Cohort N ¼111 Spanish Cohort n ¼24  Literature Review n ¼87  P Diagnostic characteristics Positive blood cultures 94 (84.7) 22 (91.7) 72/82 (87.8)  0.7 Other positive cultures 66/90 (73.3)  12 (57.1) 54/69 (78.3)  0.08 CSF 30 (33.3) 5 (25.0) 17 (31.5) Heart valves 14 (21.2) 5 (41.7) 9 (16.7) Respiratory tract 11 (12.2) 1 (8.3) 3 (5.6) Synovial fluid 4 (6.1) 0 (0) 4 (7.4) Other 6 (9.1) 2 (16.7) 5 (9.3) Antimicrobial resistance Nonpenicillin susceptible 15/74 (20.3)  1 (4.2) 14/54 (25.9)  0.05 Noncefotaxime susceptible 3/36 (8.3)  0 (0) 3/22 (13.6)  0.2 Echocardiography 109 (98.2) 24 (100) 85 (97.7) 1 TTE only 27 (24.3) 6 (25.0) 21 (36.8) TEE only 20 (18.0) 1 (4.2) 19 (33.3) Both 32 (28.8) 17 (70.8) 15 (26.3) Technique not specified 30 (27%) 0 (0%) 32 (36.8%) Ultrasound findings Vegetation 89 (80.2) 21 (87.5) 68 (78.2) 0.3 Local complication 31 (27.9) 6 (26.1) 25 (34.2) 0.6 Valve rupture 20 (18) 4 (16.7) 16 (18.4) 1 Valve abscess 9 (8.1) 1 (4.2) 8 (9.2) 0.6 Complications CNS involvement Meningitis 45 (40.5) 7 (29.2) 38 (43.7) 0.2 Embolism (stroke/abscess) 15 (13.5) 4 (16.7) 11 (12.6) 0.7 Heart failure 37 (33.3) 10 (41.7) 27 (35.5) 0.6 Embolism (excluding CNS) 31 (27.9) 7 (29.2) 24 (27.6) 1 Treatment Surgical procedure 53 (47.7) 11 (45.8) 42 (48.3) 1 Valve replacement Aortic 34 (30.6) 8 (33.3) 26 (29.9) 0.8 Mitral 15 (13.5) 3 (12.5) 12 (13.8) 1 Outcome Death 23 (20.7) 8 (33.3) 15 (17.2) 0.09 CNS ¼central nervous system, CSF ¼cerebrospinal fluid, TEE ¼transesophageal echocardiography, TTE ¼transthoracic echocardiography.  Data from the literature were missing for some variables. In those cases, the percentage was calculated using the available data as the denominator. de Egea et al Medicine Volume 94, Number 39, October 2015 6|www.md-journal.com Copyright #2015 Wolters Kluwer Health, Inc. All rights reserved. outcome. 3,81,82 In the present series, the most common underlying conditions were liver disease due to alcoholism (19.8%) and immunosuppression (10.8%). Alcoholism is a well-known predisposing factor for IPD, and its frequency varies from 10.4% to 28.1%. 3,83 The reasons for this observation are far from clear, although potential explanations include malnutrition, immunologic defects such as impaired leukocyte chemotaxis, reticuloendothelial system dysfunction, and risk of lung aspiration. 3,71 Immunosuppression affected 10.8% of the patients in our study, mainly those with HIV infection (5.4%) and malignancy (3.6%). Interestingly, a previous study of IPD in our institution reported a higher percentage of immunosuppression (44%), of which the most common causes were HIV infection (13%) and malignancy (31%). 83 These differences could be explained by the availability of highly active antiretroviral therapy and good immunological control of HIV- infected patients in recent years. Finally, previous liver disease was reported in 27.9% of cases; other authors reported previous liver disease in 12% of cases. 6,83 The classic clinical manifestations of PIE include fever and acute pneumonia with progressive heart failure, which may be fatal if appropriate treatment is not administered early. 4,74 We found pneumonia to be the first clinical manifestation of IPD in almost half of our cases (45.9%). The classic Austrian syndrome is characterized by meningitis, pneumonia, and endocarditis due to S. pneumoniae and is commonly associated with alcoholism. It was present in 26.1% of our series, and the frequency reported in the literature varied from 6.7% to 42% of cases. 3,71 Austrian syndrome seems to be a poor prognostic factor and was present in 43.5% of those who died in our series. PIE mainly affects native valves, as observed in 93.7% of the cases we report and 87 to 92% of those reported elsewhere. 6,71 Left-sided endocarditis is the most common presentation, although data on the most commonly affected valves are contradictory and vary between series. Aortic valve involvement ranges from 46.7% to 74.4%, and mitral valve involvement ranges from 31.4% to 56.7%. We found that the aortic valve was the most commonly involved (53.2%). Literature from the early 20th century suggested that PIE tends to form large vegetations that predispose to systemic embolism. 84,85 In our study, almost one-third of patients developed systemic embolism (13.5% involving the CNS), and meningitis was present in 40.5%. Starting in the 1990s, the prevalence of S. pneumoniae strains with decreased susceptibility to penicillin increased worldwide. In Spain, it ranged from 18.3% to 59%. 86,87 However, resistance to penicillin has been decreasing in recent years, possibly owing to the change in the definition of the breakpoint penicillin MIC in 2008. 9 A recent Spanish surveillance study found 28% prevalence of penicillin-resistant strains when the CNS infection cutoff MIC of >0.06 mg/L was applied; however, when the cutoff for non-CNS infection was applied (MIC >2 mg/L), the isolates all proved to be susceptible to penicillin. According to European guidelines, CNS involvement (meningitis) requires treatment with ceftriaxone or cefotaxime either alone or in combination with vancomycin. 8 In the present review, we found that 20.3% of strains were classified as nonsusceptible, although the specific MIC values were not available in the cases from the literature. In contrast, in the Spanish cohort, where MIC values were available, we calculated that with the new cutoffs, nonpenicillin-susceptible strains only accounted for 4.2%. Nevertheless, we were not able to find an association between susceptibility to penicillin and clinical outcome. Information on capsular serotypes was scarce in the literature and in our series; the most common serotypes were 18C, TABLE 4. Prognostic Factors for 111 Patients With Streptococcus pneumoniae IE (Univariate Analysis) Variable Alive 88 (79.3%) Dead 23 (20.7%) P Male 54 (61.4) 17 (73.9) 0.3 Female 34 (38.6) 6 (26.1) 0.3 CNS embolism 7 (8) 8 (34.8) <0.01 Meningitis 30 (34.1) 15 (65.2) <0.01 Surgery 49 (55.7) 4 (17.4) <0.01 Postsurgical complication 9 (18.4) 4 (100) <0.01 Surgery indication 53 (60.2) 7 (30.4) 0.02 Embolism (except CNS) 20 (22.7) 11 (47.8) 0.03 Austrian syndrome 19 (21.6) 10 (43.5) 0.05 Alcoholism 15 (18.5) 7 (33.3) 0.1 Heart failure 26 (32.9) 11 (52.4) 0.1 Pneumonia 37 (43.5) 14 (60.9) 0.1 Aortic valve involvement 44 (50) 15 (65.2) 0.2 Previous valve disease 8 (9.3) 0 (0) 0.3 Previous infective endocarditis 6 (7.5) 0 (0) 0.3 Valve rupture 14 (15.9) 6 (26.1) 0.3 Congenital heart disease 10 (11.5) 1 (4.5) 0.4 Mitral valve involvement 34 (38.6) 11 (47.8) 0.4 Tricuspid valve involvement 10 (11.4) 4 (17.4) 0.4 Intracardiac complication 24 (31.6) 7 (35) 0.7 Pulmonary valve involvement 2 (2.3) 0 (0) 1.0 Immunosuppression 10 (12.2) 2 (10) 1.0 Splenectomy or asplenia 7 (8.8) 2 (9.5) 1.0 CNS ¼central nervous system. Medicine Volume 94, Number 39, October 2015 Streptococcus Pneumoniae Endocarditis Copyright #2015 Wolters Kluwer Health, Inc. All rights reserved. www.md-journal.com |7 23F, and 8. The correlation between pneumococcal serotypes and outcome is controversial. Some studies highlight the relationship between S. pneumoniae serotypes and the risk of septic shock and higher mortality, 82,88 whereas others do not and conclude that host factors are better determinants of clinical outcome. The above-mentioned lack of data on capsular serotype from many of the patients included in this series represents a limitation for the analysis of its impact. Considering this, we could not demonstrate any association between capsular serotype and clinical manifestations, complications, or patient outcome. As for the epidemiological impact of the pneumococcal vaccines, numerous studies show a marked decrease in the prevalence of IPD. 89–93 In our series, it was difficult to prove a correlation between vaccination status and severity of infection. In Spain, data that would enable us to resolve this question are lacking. A systematic vaccination register is recommendable to evaluate whether vaccination has had an impact in the incidence of IPD. Transesophageal echocardiography was performed in 75% of cases in the Spanish cohort and in 61.8% of cases from the literature. The major echocardiographic findings were vegetations in 80.2% of patients and local complications such as valve rupture and perivalvular abscess in 26.1%. Almost half of the cohort underwent valve replacement for the IE episode. The most frequent indications for surgery in this series were inadequate control of infection source, severe sepsis, heart failure, and myocardial extension of the infection. In the multivariate analysis, this procedure was the only protective factor against mortality. In the ICE multicenter study, where 50% of patients underwent surgery, it was also reported that early surgery improved clinical outcome. Global mortality for the ICE cohort was 18%. 80 Other series presented PIE-related mortality rates ranging between 24.1% and 62%. 3,6,71 In summary, PIE continues to be a severe but very infrequent community-acquired infection. It affects patients with predisposing underlying conditions and can cause complications, such as meningitis and embolism and severe heart failure. The new MIC breakpoints for penicillin make highdose penicillin or a third-generation cephalosporin the drugs of choice. Mortality remains high despite early diagnosis and treatment, which is frequently carried out by multidisciplinary groups. Early surgery should always be considered. ACKNOWLEDGMENTS We would like to thanks Thomas O’Boyle for his help in the preparation of the manuscript, and Iva ´n Ada ´n for his help in the data management. The preliminary results of this paper were presented at 54th Interscience Conference of Antimicrobial Agents and Chemotherapy that was held in Washington, DC, on September 2014. REFERENCES 1. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae: CDC; 2013. 2. European Centre for Disease Prevention, Control. Surveillance of Invasive Bacterial Diseases in Europe. Stockholm: ECDC; 2011. 3. Aronin SI, Mukherjee SK, West JC, et al. Review of pneumococcal endocarditis in adults in the penicillin era. Clin Infect Dis. 1998;26:165–171. 4. Kan B, Ries J, Normark BH, et al. Endocarditis and pericarditis complicating pneumococcal bacteraemia, with special reference to the adhesive abilities of pneumococci: results from a prospective study. Clin Microbiol Infect. 2006;12:338–344. 5. Bayliss RCC, Oakley CM, Somerville W, et al. The microbiology and pathogenesis of infective endocarditis. Br Heart J. 1983. 6. Martinez E, Miro JM, Almirante B, et al. Effect of penicillin resistance of Streptococcus pneumoniae on the presentation, prognosis, and treatment of pneumococcal endocarditis in adults. Clin Infect Dis. 2002;35:130–139. 7. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30:633–638. 8. Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J. 2009;30:2369–2413. 9. Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis. 2009;48:1596–1600. 10. Givner LB, Mason EO Jr, Tan TQ, et al. Pneumococcal endocarditis in children. Clin Infect Dis. 2004;38:1273–1278. 11. Asbach S, Bode C, Geibel A. A severe case of Austrian syndrome. J Am Soc Echocardiogr. 2004;17:1213. 12. Akcam FZ, Yayli G, Kaya O, et al. Unusual presentation of infective endocarditis caused by Streptococcus pneumoniae on native tricuspid valve. Saudi Med J. 2005;26:334–335. 13. Al-Baradai AA, Baskett RJ, Warren AE, et al. The Ross procedure for endocarditis in a 4-month-old infant. Ann Thorac Surg. 2002;73:1973–1975. 14. Belvisi V, Del Borgo C, Morelli F, et al. Late onset invasive pneumococcal disease in a liver transplanted patient: beyond the Austrian syndrome. Transpl Infect Dis. 2013;15:E111–114. 15. Benes J, Picha D, Kabelkova M, et al. Infective endocarditis caused by unusual gram-positive pathogens. Folia Microbiol (Praha). 2002;47:737–741. 16. Booker J, Musher D. Sinusitis complicated by dural sinus thrombosis and Streptococcus pneumoniae endocarditis: a case report and review of the literature. J Infect. 2007;55:106–110. 17. Bothwell JE, Casey F, Webb CH. Tricuspid valvar endocarditis caused by penicillin resistant pneumococcus. Cardiol Young. 2001;11:556–558. 18. Butler JC, Lennox JL, McDougal LK, et al. Macrolide-resistant pneumococcal endocarditis and epidural abscess that develop during erythromycin therapy. Clin Infect Dis. 2003;36:e19–25. 19. du Cheyron D, Lesage A, Le Page O, et al. Corticosteroids as adjunctive treatment in Austrian’s syndrome (pneumococcal endocarditis, meningitis, and pneumonia): report of two cases and review of the literature. J Clin Pathol. 2003;56:879–881. 20. Choi M, Mailman TL. Pneumococcal endocarditis in infants and children. Pediatr Infect Dis J. 2004;23:166–171. 21. Dalal A, Ahmad H. Austrian syndrome (pneumococcal pneumonia, meningitis, and endocarditis): a case report. Am J Med Sci. 2008;336:354–355. 22. Endara A, Corkeron MA, Diqer AM, et al. Pneumococcal aortic valve endocarditis causing aortopulmonary artery fistula. Ann Thorac Surg. 2001;72:1737–1738. de Egea et al Medicine Volume 94, Number 39, October 2015 8|www.md-journal.com Copyright #2015 Wolters Kluwer Health, Inc. All rights reserved. 23. Esteva F, Ruiz Macarilla S, Vidal N. A 52-year-old male with meningitis and pneumococcal sepsis with fatal outcome. Med Clin (Barc). 2002;119:109–116. 24. Favre G, Remy V, Martinot M, et al. Haematogenous brain abscess complicating a case of Austrian syndrome. Scand J Infect Dis. 2003;35:275–276. 25. Garcia Ordonez MA, Hierro Martin I, Jimenez Martin JJ, et al. Fulminant pneumococcal pancarditis and acute myocardial infarction with cardiac failure. An Med Interna. 2006;23:285–287. 26. Gonzalez-Juanatey C, Testa A, Mayo J, et al. Austrian syndrome: report of two new cases and literature review. Int J Cardiol. 2006;108:273–275. 27. Hristea A, Nicolae D, Luka AI, et al. Invasive pneumococcal infections: Austrian syndrome. Rom J Intern Med. 2009;47:93–96. 28. Ishiwada N, Niwa K, Tateno S, et al. Pneumococcal endocarditis in children: a nationwide survey in Japan. Int J Cardiol. 2008;123:298– 301. 29. Kanakadandi V, Annapureddy N, Agarwal SK, et al. The Austrian syndrome: a case report and review of the literature. Infection. 2013;41:695–700. 30. Luzzati R, Pinamonti B, Giacomazzi D, et al. Aortic-right atrium fistula complicating Austrian syndrome: a case report and literature review. Infez Med. 2007;15:124–128. 31. Mankongpaisarnrung C, Soontrapa S, Nantsupawat T, et al. Renal infarction as a presentation of Austrian syndrome: thromboembolic phenomenon of pneumococcal endocarditis. Am J Med Sci. 2012;344:251–254. 32. Midon ME, Goldoni F, Souza SG, et al. Austrian Syndrome: case report. Arq Bras Cardiol. 2011;97:e50–52. 33. Murillo Valles M. Endocarditis neumoco´cica en nin ˜o de 17 meses previamente sano. Anales de Pediatrı ´a. 2007;66:615–618. 34. Novak PG, Isserow S, Gudas V, et al. Transesophageal echocardiographic identification of an aortic root to right atrial fistula in a patient with acute streptococcal aortic valve bacterial endocarditis. J Am Soc Echocardiogr. 2003;16:497–498. 35. O’Brien S, Dayer M, Benzimra J, et al. Streptococcus pneumoniae endocarditis on replacement aortic valve with panopthalmitis and pseudoabscess. BMJ Case Rep. 20112011. 36. Patra KP, Vanchiere JA, Bocchini JA Jr et al. Endocarditis with ruptured sinus of Valsalva aneurysm caused by nonvaccine Streptococcus pneumoniae serotype 21. Tex Heart Inst J. 2012;39: 277–280. 37. Porres-Aguilar M, Flavin NE, Fleming RV, et al. Severe bivalvular pneumococcal endocarditis and suppurative pericarditis in an immunocompetent patient. Intern Med. 2010;49:321–323. 38. Poulsen JB, Moser C, Espersen K, et al. Austrian syndrome. BMJ Case Rep. 20112011. 39. Rammeloo L, Hruda J, Sobotka-Plojhar M, et al. Austrian syndrome in a child-aortic valve endocarditis following pneumococcal meningitis. Int J Cardiol. 2004;94:321–322. 40. Christensen SR, Hansen AB, La Cour M, et al. Bilateral endogenous bacterial endophthalmitis: a report of four cases. Acta Ophthalmol Scand. 2004;82 (3 Pt 1):306–310. 41. Siegel M, Timpone J. Penicillin-resistant Streptococcus pneumoniae endocarditis: a case report and review. Clin Infect Dis. 2001;32: 972–974. 42. Sewlall NH, Tikly M. Invasive pneumococcal infection presenting as septic arthritis and Austrian-like syndrome involving the tricuspid valve in a patient with underlying HIV infection. Joint Bone Spine. 2005;72:86–88. 43. Solorio A. Endocarditis por Streptococcus pneumoniae en un escolar sano. Anales de Pediatrı ´a. 2008;69:366–368. 44. Subira C, Perez H, Anglada M, et al. Austrian syndrome. Med Intensiva. 2010;34:155–156. 45. Takabayashi S, Shimpo H, Miyake Y, et al. Performance of the Fontan procedure using extra-cardiac direct anastomosis on patients treated for penicillin-resistant Streptococcus pneumoniae endocarditis. Jpn J Thorac Cardiovasc Surg. 2005;53:176–179. 46. Tan M, Armstrong D, Birken C, et al. Bacterial endocarditis in a child presenting with acute arterial ischemic stroke: should thrombolytic therapy be absolutely contraindicated? Dev Med Child Neurol. 2009;51:151–154. 47. Tanawuttiwat T, Poustinchian B, Treitman A, et al. Pneumococcal endocarditis with extremely rapid valve destruction in a splenectomized host. J Heart Valve Dis. 2011;20:596–598. 48. Tesfaye H, Lukaskova J, Horinkova J. Sudden renal function deterioration in an elderly patient on vancomycin therapy for endocarditis. Cas Lek Cesk. 2012;151:531–534. 49. Trotter JM, Aru G, Fox ER. Austrian triad with sinus of Valsalva aneurysm and rupture. Ann Thorac Surg. 2006;82:1525–1527. 50. Tsang M, Perera S, Lonn E, et al. Pneumococcal endocarditis causing valve destruction in the absence of vegetations on transesophageal echocardiography: a series of 3 consecutive cases. Can J Cardiol. 2013;29:519e517–e519. 51. Uemura L, Grassi NC, Cazarin L. Pneumococcal endocarditis of subacute evolution. Arq Bras Cardiol. 2001;76:319–322. 52. Valero B. El curso clı´nico agresivo de la endocarditis neumoco´cica. Revista Clı ´nica Espan ˜ola. 2007;207:183–186. 53. Velazquez C, Araji O, Barquero JM, et al. Austrian syndrome: a clinical rarity. Int J Cardiol. 2008;127:e36–e38. 54. Vindas-Cordero JP, Sands M, Sanchez W. Austrian’s triad complicated by suppurative pericarditis and cardiac tamponade: a case report and review of the literature. Int J Infect Dis. 2009;13:e23– e25. 55. Voldstedlund M, Pedersen LN, Fuursted K, et al. Different polymerase chain reaction-based analyses for culture-negative endocarditis caused by Streptococcus pneumoniae.Scand J Infect Dis. 2003;35:757–759. 56. Watanabe Y, Taketani Y, Takei Y, et al. Complete heart block resulting from quadricuspid aortic valve penicillin-resistant pneumococcal endocarditis: a case report. Circ J. 2003;67:275–276. 57. Wenzel AM, Tager FM, Burgos LR, et al. Pneumococcal endocarditis in children: report of a case due to penicillin resistant Streptococcus pneumoniae.Rev Chilena Infectol. 2006;23:243–246. 58. White B, Diggle M, Todd A, et al. A novel pneumococcus with a new association. Travel Med Infect Dis. 2011;9:84–87. 59. Wilbring M, Tugtekin SM, Matschke K, et al. Austrian syndrome in the context of a fulminant pneumococcal native valve endocarditis. Braz J Infect Dis. 2012;16:486–488. 60. Wong V, Adams J, Jones MI, et al. Pneumococcal endoprosthetic pulmonary valve endocarditis with crescentic glomerulonephritis and acute renal failure. Clin Nephrol. 2009;71:318–320. 61. Yusuf J, Ahmad K, Mazumder S, et al. Streptococcus pneumoniaeassociated pneumonia, meningitis, and endocarditis: a case of Austrian syndrome. J La State Med Soc. 2012;164:324–326. 62. Vandenbos F, Roth S, Montagne N. Endocarditis, meningitis, pneumopathy and pneumococcal cerebral abscess in an alcoholic smoker. Rev Mal Respir. 2001;18:545–547. 63. Benillouche-Abitbol E, Chauvat A, Hannoun A, et al. Pneumococcal endocarditis in native valves. Three original observations in the adult. Arch Mal Coeur Vaiss. 2002;95:919–923. 64. Madsen RG, Ladefoged K, Kjaergaard JJ, et al. Endocarditis in Greenland with special reference to endocarditis caused by Streptococcus pneumoniae.Int J Circumpolar Health. 2009;68:347–353. Medicine Volume 94, Number 39, October 2015 Streptococcus Pneumoniae Endocarditis Copyright #2015 Wolters Kluwer Health, Inc. All rights reserved. www.md-journal.com |9